Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
Crossref DOI link: https://doi.org/10.1007/s12032-015-0683-y
Published Online: 2015-08-27
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Miyata, Yasuyoshi
Asai, Akihiro
Mitsunari, Kensuke
Matsuo, Tomohiro
Ohba, Kojiro
Sakai, Hideki
Funding for this research was provided by:
a Grant-in-Aid from Japan Society for the Promotion of Science (No. 25462487)
License valid from 2015-08-27